First-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature.

Journal: Frontiers in immunology

PMID: 39850892

Abstract

BACKGROUND: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) exhibit a notably aggressive phenotype, which is associated with poor patient survival outcomes. These tumors are generally resistant to conventional cytotoxic chemotherapy, thereby limiting the availability of effective treatment options.

Authors

Xiaoling Wei

Department of Respiratory Medicine, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiangju Xing

Department of Respiratory Medicine, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Wei Yao

Department of Respiratory Medicine, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Changzheng Wang

Department of Respiratory Medicine, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yajie Xiao

Department of Translational Medicine, Shenzhen Yucebio Technology Co., Ltd., Shenzhen, China.
Xianzhi Du

Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Keywords

Acquired Immunodeficiency Syndrome Aged Angiogenesis Inhibitors Antineoplastic Combined Chemotherapy Protocols DNA Helicases Humans Immunotherapy Lung Neoplasms Male Nuclear Proteins Thoracic Neoplasms Transcription Factors

External Resources

View on PubMed Access via DOI PubMed (39850892)

First-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals